HC Wainwright Issues Pessimistic Outlook for AMLX Earnings

Key Points

• HC Wainwright lowered its Q3 2026 EPS estimate for Amylyx Pharmaceuticals to a loss of $0.35 per share from $0.33, while maintaining a Buy rating and a $34 price target.
• Amylyx reported a quarterly loss of $0.39 per share, missing the $0.36 consensus estimate by $0.03. Analysts overall remain moderately bullish, with a consensus price target of $25.38.
• The stock opened at $22.67, down 0.7%, after rising from a 52-week low of $7.61; institutional investors own approximately 95.84% of the company.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) - Analysts at HC Wainwright cut their Q3 2026 earnings estimates for shares of Amylyx Pharmaceuticals in a research report issued on Friday, August 7th. HC Wainwright analyst A. Fein now expects that the company will earn ($0.35) per share for the quarter, down from their previous estimate of ($0.33). HC Wainwright has a "Buy" rating and a $34.00 price target on the stock. The consensus estimate for Amylyx Pharmaceuticals' current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Amylyx Pharmaceuticals' Q4 2026 earnings at ($0.37) EPS, FY2026 earnings at ($1.49) EPS, FY2027 earnings at ($1.40) EPS and FY2028 earnings at ($1.08) EPS.

AMLX has been the topic of several other reports. Citigroup upped their price objective on Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the company a "buy" rating in a research report on Monday, August 3rd. Wall Street Zen lowered Amylyx Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, May 9th. Weiss Ratings restated a "sell (d-)" rating on shares of Amylyx Pharmaceuticals in a research note on Wednesday, August 5th. Mizuho upped their price target on Amylyx Pharmaceuticals from $21.00 to $24.00 and gave the company an "outperform" rating in a report on Monday, July 20th. Finally, Guggenheim increased their price objective on Amylyx Pharmaceuticals from $30.00 to $40.00 and gave the company a "buy" rating in a research report on Thursday, June 25th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $25.38.

Amylyx Pharmaceuticals Stock Down 0.7%

NASDAQ:AMLX opened at $22.67 on Tuesday. The stock has a market cap of $2.53 billion, a price-to-earnings ratio of -15.85 and a beta of -0.21. The company's 50 day moving average price is $17.54 and its 200-day moving average price is $15.81. Amylyx Pharmaceuticals has a 52 week low of $7.61 and a 52 week high of $24.60.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.03).

Insider Activity

In related news, insider Gina Mazzariello sold 15,000 shares of Amylyx Pharmaceuticals stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $18.32, for a total value of $274,800.00. Following the completion of the sale, the insider owned 194,090 shares of the company's stock, valued at $3,555,728.80. The trade was a 7.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 10.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Amylyx Pharmaceuticals by 10.1% in the fourth quarter. Vanguard Group Inc. now owns 5,804,912 shares of the company's stock worth $70,123,000 after buying an additional 531,162 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Amylyx Pharmaceuticals by 15.5% during the 1st quarter. Bank of New York Mellon Corp now owns 251,104 shares of the company's stock valued at $3,490,000 after buying an additional 33,757 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Amylyx Pharmaceuticals by 17.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 903,192 shares of the company's stock valued at $12,544,000 after acquiring an additional 131,944 shares during the period. iA Global Asset Management Inc. bought a new position in shares of Amylyx Pharmaceuticals during the 1st quarter valued at approximately $4,237,000. Finally, Siren L.L.C. bought a new position in shares of Amylyx Pharmaceuticals during the 1st quarter valued at approximately $17,097,000. 95.84% of the stock is owned by hedge funds and other institutional investors.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company's lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source